NO20080553L - Azinyl-3-sulfonylindazolderivater som 5-hydroksytrypyamin-6 ligander - Google Patents

Azinyl-3-sulfonylindazolderivater som 5-hydroksytrypyamin-6 ligander

Info

Publication number
NO20080553L
NO20080553L NO20080553A NO20080553A NO20080553L NO 20080553 L NO20080553 L NO 20080553L NO 20080553 A NO20080553 A NO 20080553A NO 20080553 A NO20080553 A NO 20080553A NO 20080553 L NO20080553 L NO 20080553L
Authority
NO
Norway
Prior art keywords
hydroxytrypyamine
azinyl
ligands
sulfonylindazole
derivatives
Prior art date
Application number
NO20080553A
Other languages
English (en)
Inventor
Hassan Mahmoud Elokdah
Albert J Robichaud
Alexander Alexei Greenfield
Kevin Liu
Geraldine Ruth Mcfarlane
Jennifer Rebecca Lo
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20080553L publication Critical patent/NO20080553L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer en forbindelse med formel I og anvendelsen av denne for behandling av en sentralnervøs forstyrrelse, som er relatert til eller som påvirkes av 5-HT6-reseptoren. Foreliggende oppfinnelse tilveiebringer en forbindelse med formel I og anvendelsen av denne for behandling av en sentralnervøs forstyrrelse, som er relatert til eller som påvirkes av 5-HT6-reseptoren.
NO20080553A 2005-08-15 2008-01-30 Azinyl-3-sulfonylindazolderivater som 5-hydroksytrypyamin-6 ligander NO20080553L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70831705P 2005-08-15 2005-08-15
PCT/US2006/030837 WO2007032833A1 (en) 2005-08-15 2006-08-08 Azinyl-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands

Publications (1)

Publication Number Publication Date
NO20080553L true NO20080553L (no) 2008-04-23

Family

ID=37315656

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080553A NO20080553L (no) 2005-08-15 2008-01-30 Azinyl-3-sulfonylindazolderivater som 5-hydroksytrypyamin-6 ligander

Country Status (21)

Country Link
US (1) US7790751B2 (no)
EP (1) EP1915348A1 (no)
JP (1) JP2009504738A (no)
KR (1) KR20080034497A (no)
CN (1) CN101291913A (no)
AR (1) AR056459A1 (no)
AU (1) AU2006291414A1 (no)
BR (1) BRPI0614341A2 (no)
CA (1) CA2619309A1 (no)
CR (1) CR9733A (no)
EC (1) ECSP088176A (no)
GT (1) GT200600374A (no)
IL (1) IL189416A0 (no)
MX (1) MX2008002158A (no)
NO (1) NO20080553L (no)
PE (1) PE20070373A1 (no)
RU (1) RU2008103700A (no)
SV (1) SV2008002653A (no)
TW (1) TW200800913A (no)
WO (1) WO2007032833A1 (no)
ZA (1) ZA200801524B (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2619010C (en) * 2005-08-15 2013-10-01 Wyeth Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands
WO2008010087A2 (en) * 2006-07-14 2008-01-24 Ranbaxy Laboratories Limited Polymorphic forms of an hmg-coa reductase inhibitor and uses thereof
WO2008055847A1 (en) * 2006-11-09 2008-05-15 F. Hoffmann-La Roche Ag Arylsulfonyl pyrrolidines as 5-ht6 inhibitors
CA2685318A1 (en) 2007-05-15 2008-11-27 Wyeth 5-(aminoazacyclyl)-3-sulfonyl-1h-indazoles as 5-hydroxytryptamine-6 ligands for the treatment of cns disorders
US20090012308A1 (en) * 2007-06-13 2009-01-08 Wyeth Process for the manufacture of benzylsulfonylarenes
CN106986875A (zh) * 2009-04-23 2017-07-28 Abbvie 公司 5‑ht受体的调节剂和其使用方法
US8518933B2 (en) * 2009-04-23 2013-08-27 Abbvie Inc. Modulators of 5-HT receptors and methods of use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK6252000A3 (en) 1997-11-04 2001-11-06 Pfizer Prod Inc Indazole bioisostere replacement of catechol in therapeutically active compounds
CA2378047A1 (en) 1999-07-15 2001-01-25 Methvin Isaac Heterocyclic compounds for the treatment of migraine
CA2432654A1 (en) * 2000-12-22 2002-07-04 Wyeth Heterocyclindazole and azaindazole compounds as 5-hydroxytryptamine-6 ligands
CA2444036A1 (en) * 2001-04-20 2002-10-31 Yanfang Li Heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
MXPA03009476A (es) 2001-04-20 2004-02-12 Wyeth Corp Derivados de heterocicliloxi-,-tioxi-y-aminobenzazol como ligandos de 5-hidroxitriptamina-6.
US7199147B2 (en) 2001-06-12 2007-04-03 Dainippon Sumitomo Pharma Co., Ltd. Rho kinase inhibitors
US20050113283A1 (en) 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
TW200400177A (en) 2002-06-04 2004-01-01 Wyeth Corp 1-(Aminoalkyl)-3-sulfonylindole and-indazole derivatives as 5-hydroxytryptamine-6 ligands
US7943639B2 (en) 2002-06-20 2011-05-17 Proximagen Limited Compounds
TW200401641A (en) * 2002-07-18 2004-02-01 Wyeth Corp 1-Heterocyclylalkyl-3-sulfonylindole or-indazole derivatives as 5-hydroxytryptamine-6 ligands
TW200412945A (en) * 2002-10-25 2004-08-01 Upjohn Co Quaternary ammonium compounds
PL378120A1 (pl) 2003-02-14 2006-03-06 Wyeth Heterocyklilo-3-sulfonyloindazole jako ligandy 5-hydroksytryptaminy
WO2005085206A1 (en) 2004-02-27 2005-09-15 F. Hoffmann-La Roche Ag Indazole derivatives and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
CR9733A (es) 2008-04-02
JP2009504738A (ja) 2009-02-05
BRPI0614341A2 (pt) 2011-03-29
ECSP088176A (es) 2008-04-28
RU2008103700A (ru) 2009-09-27
EP1915348A1 (en) 2008-04-30
KR20080034497A (ko) 2008-04-21
AR056459A1 (es) 2007-10-10
CA2619309A1 (en) 2007-03-22
IL189416A0 (en) 2008-06-05
GT200600374A (es) 2007-03-29
US20070054896A1 (en) 2007-03-08
AU2006291414A1 (en) 2007-03-22
PE20070373A1 (es) 2007-04-04
WO2007032833A1 (en) 2007-03-22
ZA200801524B (en) 2010-04-28
MX2008002158A (es) 2008-04-19
SV2008002653A (es) 2008-04-11
TW200800913A (en) 2008-01-01
US7790751B2 (en) 2010-09-07
CN101291913A (zh) 2008-10-22

Similar Documents

Publication Publication Date Title
NO20050007L (no) 1-Heterosyklylalkyl-3-sulfonylazaindol eller -azaindazolderivater som 5-hydroksytryptamin-6 ligander
NO20050014L (no) 1-Heterosyklylalkyl-3-sulfonylindol eller -indazolderivater som 5-hydroksytryptamin-6 ligander
NO20082136L (no) 1,5-substituerte indol-2-yl-amidderivater
NO20081454L (no) Met-kinaseinhibitorer
NO20082096L (no) Azaindol-2-karboksamidderivativer
WO2007142905A3 (en) 1-sulfonylindazolylamine and -amide derivatives as 5-hydroxytryptamine-6 ligands
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
EA200970402A1 (ru) Триазолопиридазиновые модуляторы протеинкиназ
NO20075082L (no) Pyridin-3-karboksamidderivater som CB1-inversagonister
MA32508B1 (fr) Composes organiques
NO20060202L (no) Pyrrolodihydroisokinoliner som PDE-10-inhibitorer
NO20075624L (no) Nye histamin H3-reseptorligander og deres terapeutiske anvendelser
NO20080981L (no) Nitrocatechol-derivater som COMT-inhibitorer
NO20093009L (no) Kondensert ring heterocykel kinase modulatorer
DK1771178T3 (da) Anvendelse af K-252A og kinaseinhibitorer til forebyggelse eller behandling af HMGB1-assocuerede patologiske tilstande
NO20082090L (no) Pyridopyrimidinoninhibitorer av P13K alfa
EA200901488A1 (ru) Замещенные имидазолопиридазины, как ингибиторы липидкиназы
NO20075406L (no) Pyrimidindionerivater som prokineticin-2-reseprorantagonister
NO20082285L (no) 3-aminosyklopentankarboksamider som modulatorer av kjemokinreseptorer
EA200601895A1 (ru) 3-(4-гетероарилциклогексиламино)циклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов
NO20082939L (no) Sykloheksyl piperasinyl metanon derivater og anvendelse av disse som histamin H3 reseptor modulatorer
ATE445593T1 (de) Acetylenderivate
NO20080553L (no) Azinyl-3-sulfonylindazolderivater som 5-hydroksytrypyamin-6 ligander
NO20083058L (no) Cykloheksylsulfonamidderivater med H3 reseptor aktivitet
NO20080937L (no) Substituerte-3-sulfonylindazolderivater som 5-hydroksytryptamin-6-ligander

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application